Trial Profile

A 2-part, multicenter, open-label, phase Ib/II study assessing the Tazemetostat's safety and efficacy in combination with a PARPi or checkpoint inhibitor in patients with Small cell lung cancer, metastatic castration-resistant Prostate cancer and Ovarian cancer

Status: Not yet recruiting

Phase of Trial: Phase I/II

Latest Information Update: 19 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tazemetostat (Primary) ; Carboplatin; Cisplatin; Durvalumab; Etoposide; Olaparib; Rucaparib
Indications Ovarian cancer; Prostate cancer; Small cell lung cancer
Focus Adverse reactions; Therapeutic Use

19 Nov 2021 Planned number of patients changed to 84.
17 Nov 2021 New trial record
21 Sep 2021 Study Design presented at the 46th European Society for Medical Oncology Congress

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com